Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

Genetics in Medicine

Volumn 11, Issue 9, 2009, Pages 624-628

  Daniels, Molly S ^a   Urbauer, Diana L ^a   Stanley, Jennifer L ^a   Johnson, Kristin G ^a   Lu, Karen H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

BRCA1; BRCA2; Cancer recurrence; Genetic testing; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER;

BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 70349706039     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181ab2295     Document Type: Article

References (25)

1. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society, 2008.
2. Malander S, Ridderheim M, Masback A, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004;40:422-428.
3. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005; 104:2807-2816.
4. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710.
5. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 2006;66:8297-8308.
6. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7817.
7. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851- 1860.
8. Hampel H, Panescu J, Lockman J, et al. Comment on: screening for lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2007;67:9603.
9. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20:463-466.
10. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCAlinked and sporadic ovarian cancer. JAMA 2000;283:2260-2265.
11. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003; 97:2187-2195.
12. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the National Israeli study of ovarian cancer. J Clin Oncol 2008;26:20-25.
13. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-1416.
14. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-182.
15. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004;95:866-871.
16. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADPribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-1388.
17. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2- deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-917.
18. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-921.
19. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M, editors. Principles and practice of gynecologic oncology, 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2005:895-988.
20. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001;19:1266-1274.
21. von Gruenigen VE, Frasure HE, Reidy AM, Gil KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol. 2003;90:619-624.
22. Vigano A, Dorgan M, Bruera E, Suarez-Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999;86:170-176.
23. van Oostrom I, Meijers-Heijboer H, Duivenvoorden HJ, et al. A prospective study of the impact of genetic susceptibility testing for BRCA1/2 or HNPCC on family relationships. Psychooncology 2007;16:320-328.
24. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2007;107:159-162.
25. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM: Genetic/familial high risk assessment: breast and ovarian. VI: National Comprehensive Cancer Network, 2008.